{"gene":"SARS1","run_date":"2026-06-10T07:46:29","timeline":{"discoveries":[{"year":2022,"finding":"A missense variant in SARS1 (p.Arg213Leu) located directly within the enzyme's active site likely diminishes seryl-tRNA synthetase aminoacylation activity, as demonstrated by structural mapping placing the variant at the active site; patients with biallelic SARS1 variants present with microcephaly, developmental delay, intellectual disability, and brain anomalies.","method":"Structural mapping of variant onto SARS1 protein structure; clinical genetics with biallelic variant identification","journal":"Human mutation","confidence":"Low","confidence_rationale":"Tier 3 / Weak — structural mapping only (no in vitro enzymatic assay reported in abstract), single lab, no direct biochemical validation of activity reduction described","pmids":["35790048"],"is_preprint":false},{"year":2022,"finding":"A de novo splice site deletion in SARS1 causing a 5-amino acid in-frame insertion near the active site results in loss-of-function with a dominant negative effect, as shown by complementation assays in S. cerevisiae and serylation assays in yeast and patient fibroblasts. Loss of SARS1 function causes cellular senescence, including abnormal cell shape, arrested division, increased beta-galactosidase staining, and elevated senescence-associated secretory phenotype markers (IL-6, p21, p16, p53).","method":"Yeast complementation assay; serylation (aminoacylation) activity assay in yeast and patient fibroblasts; beta-galactosidase staining; immunofluorescence/cell morphology; SASP marker measurement","journal":"Journal of medical genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct enzymatic (serylation) assay confirming loss of function, complementation assay in yeast model, multiple orthogonal methods (enzymatic activity + cell biology phenotypes), single lab","pmids":["36041817"],"is_preprint":false},{"year":2021,"finding":"A biallelic missense variant in SARS1 (p.Arg213Leu) leads to protein instability, reduced protein level, and reduced enzymatic (seryl-tRNA synthetase) activity, causing a neurodevelopmental syndrome including developmental delay, central deafness, cardiomyopathy, and metabolic decompensation.","method":"Protein stability assessment; enzymatic activity assay for aminoacylation in patient-derived cells; clinical genetics","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct enzymatic activity measurement and protein level quantification, single lab, two orthogonal methods","pmids":["34570399"],"is_preprint":false},{"year":2024,"finding":"Human cytosolic SARS1 (SerRS) interacts with m3C32 tRNA methyltransferases, coordinates tRNA modification and aminoacylation; when translocated to the nucleus, SerRS acts as a negative regulator of VEGFA gene expression by competing with transcription factors NFκB1 and c-Myc, forming complexes with YY1 and SIRT2. SerRS phosphorylation in hypoxia diminishes its binding to the VEGFA promoter, and nutrient deprivation triggers SerRS glycosylation that reduces its nuclear localization. SerRS also binds telomeric DNA and cooperates with shelterin protein POT1 to regulate telomere length and cellular senescence.","method":"Review/synthesis of prior experimental findings including co-immunoprecipitation, nuclear localization experiments, chromatin immunoprecipitation, post-translational modification studies (phosphorylation/glycosylation), and protein interaction assays (cited from primary literature reviewed)","journal":"Life (Basel, Switzerland)","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — review paper summarizing multiple experimental results from prior primary studies; individual findings supported by multiple orthogonal methods across studies, but this corpus only contains the review abstract","pmids":["38255739"],"is_preprint":false},{"year":2025,"finding":"SARS1 (seryl-tRNA synthetase 1) is identified as a pan-essential target protein in the context of HPV-positive cancer cells; the HPV E6 viral E3 ubiquitin ligase can be used to degrade SARS1 via VIPER-TAC bifunctional molecules, selectively killing E6-expressing cancer cells.","method":"Targeted protein degradation (VIPER-TAC) in HPV-positive cervical cancer cell model; cell viability assay","journal":"Cell chemical biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single-lab proof-of-concept, demonstrates degradability of SARS1 via exogenous E3 ligase but does not characterize SARS1's own enzymatic mechanism; no direct mechanistic study of SARS1 function","pmids":["40049166"],"is_preprint":false}],"current_model":"SARS1 (seryl-tRNA synthetase 1) is a cytosolic aminoacyl-tRNA synthetase that catalyzes the ligation of serine to its cognate tRNA (serylation), an essential step in protein synthesis; loss-of-function variants cause neurodevelopmental disorders with a dominant negative or recessive mechanism, and SARS1 has non-canonical roles including nuclear translocation to repress VEGFA transcription (in complex with YY1 and SIRT2), interaction with m3C32 tRNA methyltransferases, binding of telomeric DNA in cooperation with POT1 to regulate telomere length, and regulation of cellular senescence."},"narrative":{"mechanistic_narrative":"SARS1 (seryl-tRNA synthetase 1) is a cytosolic aminoacyl-tRNA synthetase that ligates serine to its cognate tRNA, an essential step in protein synthesis whose loss is incompatible with normal cellular maintenance [PMID:36041817]. Direct serylation assays in patient fibroblasts and yeast complementation establish that disease-associated SARS1 variants impair aminoacylation activity, and loss of function drives cellular senescence marked by arrested division, beta-galactosidase accumulation, and elevated SASP factors (IL-6, p21, p16, p53) [PMID:36041817]. A recurrent biallelic active-site missense variant (p.Arg213Leu) destabilizes the protein and reduces enzymatic activity, causing a neurodevelopmental syndrome with developmental delay, deafness, cardiomyopathy, and metabolic decompensation [PMID:34570399]; SARS1 variants are thus causative of recessive and dominant-negative neurodevelopmental disorders [PMID:36041817, PMID:34570399]. Beyond catalysis, SARS1 coordinates tRNA modification through interaction with m3C32 tRNA methyltransferases and exerts non-canonical nuclear functions, including repression of VEGFA transcription in complexes with YY1 and SIRT2 and binding of telomeric DNA in cooperation with POT1 to regulate telomere length, with these activities tuned by hypoxia-driven phosphorylation and nutrient-dependent glycosylation [PMID:38255739]. SARS1 is a pan-essential dependency that can be selectively degraded in HPV-positive cancer cells [PMID:40049166].","teleology":[{"year":2021,"claim":"Establishing whether a recurrent SARS1 active-site variant is biochemically deleterious connected the gene to a defined neurodevelopmental syndrome and showed the mechanism is protein destabilization plus catalytic loss, not merely sequence change.","evidence":"Protein stability assessment and aminoacylation activity assay in patient-derived cells with clinical genetics","pmids":["34570399"],"confidence":"Medium","gaps":["Did not test rescue/complementation to formally prove causality","Mechanism by which the variant destabilizes the protein not structurally resolved","Tissue-specific basis of the syndrome (deafness, cardiomyopathy) not addressed"]},{"year":2022,"claim":"Mapping a biallelic missense variant to the active site and linking biallelic SARS1 to microcephaly and brain anomalies extended the disease phenotype but rested only on structural inference of activity loss.","evidence":"Structural mapping of the variant onto SARS1 structure with biallelic-variant clinical genetics","pmids":["35790048"],"confidence":"Low","gaps":["No in vitro enzymatic assay reported to confirm the predicted activity reduction","Single lab, no functional rescue","Genotype-phenotype correlation across SARS1 patients not unified"]},{"year":2022,"claim":"Direct serylation and yeast complementation assays proved that a SARS1 splice variant causes loss of function with a dominant-negative effect and, critically, that this loss drives cellular senescence — connecting tRNA charging deficiency to a defined cellular phenotype.","evidence":"Yeast complementation, serylation assays in yeast and patient fibroblasts, beta-galactosidase staining, morphology, and SASP marker measurement","pmids":["36041817"],"confidence":"High","gaps":["Molecular route from aminoacylation loss to senescence induction not delineated","Whether dominant-negative action reflects subunit poisoning not directly shown","In vivo organismal phenotype not modeled"]},{"year":2024,"claim":"Synthesis of prior primary data positioned SARS1 as a moonlighting protein beyond translation — coordinating tRNA modification, repressing VEGFA transcription in the nucleus, and binding telomeric DNA — defining a regulatory dimension to its biology.","evidence":"Review consolidating co-IP, nuclear localization, ChIP, post-translational modification, and interaction assays from prior studies","pmids":["38255739"],"confidence":"Medium","gaps":["Corpus contains only the review abstract, not the underlying primary datasets","Signals controlling nuclear translocation versus cytosolic catalysis not fully mapped","Functional contribution of telomeric/VEGFA roles to the disease phenotype unestablished"]},{"year":2025,"claim":"Demonstrating that SARS1 is a pan-essential protein degradable via the HPV E6 E3 ligase showed it can be exploited as a selective vulnerability in virus-positive cancer cells.","evidence":"VIPER-TAC targeted degradation in HPV-positive cervical cancer cells with viability readout","pmids":["40049166"],"confidence":"Low","gaps":["Proof-of-concept degradation only; does not characterize SARS1's own catalytic mechanism","Selectivity and off-target effects in non-cancer cells not detailed","Single-lab study"]},{"year":null,"claim":"How SARS1's non-canonical nuclear and telomeric functions are mechanistically coupled to — or separable from — its essential aminoacylation activity, and how each contributes to senescence and neurodevelopmental disease, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model linking active-site variants to dominant-negative subunit behavior","Direct primary evidence for VEGFA/telomere roles absent from this corpus","Causal chain from charging defect to senescence and tissue pathology undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[1,2]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[1,3]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,3]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,2]}],"complexes":[],"partners":["YY1","SIRT2","POT1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P49591","full_name":"Serine--tRNA ligase, cytoplasmic","aliases":["Seryl-tRNA synthetase","SerRS","Seryl-tRNA(Ser/Sec) synthetase"],"length_aa":514,"mass_kda":58.8,"function":"Catalyzes the attachment of serine to tRNA(Ser) in a two-step reaction: serine is first activated by ATP to form Ser-AMP and then transferred to the acceptor end of tRNA(Ser) (PubMed:22353712, PubMed:24095058, PubMed:26433229, PubMed:28236339, PubMed:34570399, PubMed:36041817, PubMed:9431993). Is probably also able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into selenocysteinyl-tRNA(Sec) (PubMed:26433229, PubMed:28236339, PubMed:34570399, PubMed:9431993). In the nucleus, binds to the VEGFA core promoter and prevents MYC binding and transcriptional activation by MYC (PubMed:24940000). Recruits SIRT2 to the VEGFA promoter, promoting deacetylation of histone H4 at 'Lys-16' (H4K16). Thereby, inhibits the production of VEGFA and sprouting angiogenesis mediated by VEGFA (PubMed:19423847, PubMed:19423848, PubMed:24940000)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P49591/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/SARS1","classification":"Common Essential","n_dependent_lines":1208,"n_total_lines":1208,"dependency_fraction":1.0},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000031698","cell_line_id":"CID001746","localizations":[{"compartment":"cytoplasmic","grade":3}],"interactors":[{"gene":"SAR1B","stoichiometry":0.2},{"gene":"SLC25A6","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001746","total_profiled":1310},"omim":[{"mim_id":"620317","title":"NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY AND SPEECH DELAY, WITH OR WITHOUT BRAIN ABNORMALITIES; NEDMSBA","url":"https://www.omim.org/entry/620317"},{"mim_id":"618903","title":"METHYLTRANSFERASE 6, METHYLCYTIDINE; METTL6","url":"https://www.omim.org/entry/618903"},{"mim_id":"617709","title":"NEURODEVELOPMENTAL DISORDER WITH MICROCEPHALY, ATAXIA, AND SEIZURES; NEDMAS","url":"https://www.omim.org/entry/617709"},{"mim_id":"607529","title":"SERYL-tRNA SYNTHETASE 1; SARS1","url":"https://www.omim.org/entry/607529"},{"mim_id":"191050","title":"TRYPTOPHANYL-tRNA SYNTHETASE 1; WARS1","url":"https://www.omim.org/entry/191050"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SARS1"},"hgnc":{"alias_symbol":["SERS"],"prev_symbol":["SARS"]},"alphafold":{"accession":"P49591","domains":[{"cath_id":"1.10.287.40","chopping":"6-135","consensus_level":"high","plddt":94.7602,"start":6,"end":135},{"cath_id":"3.30.930.10","chopping":"155-470","consensus_level":"high","plddt":96.7067,"start":155,"end":470}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P49591","model_url":"https://alphafold.ebi.ac.uk/files/AF-P49591-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P49591-F1-predicted_aligned_error_v6.png","plddt_mean":93.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SARS1","jax_strain_url":"https://www.jax.org/strain/search?query=SARS1"},"sequence":{"accession":"P49591","fasta_url":"https://rest.uniprot.org/uniprotkb/P49591.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P49591/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P49591"}},"corpus_meta":[{"pmid":"33608407","id":"PMC_33608407","title":"SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.","date":"2021","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/33608407","citation_count":85,"is_preprint":false},{"pmid":"33744314","id":"PMC_33744314","title":"SARS-CoV-2 Fusion Peptide has a Greater Membrane Perturbating Effect than SARS-CoV with Highly Specific Dependence on Ca2.","date":"2021","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/33744314","citation_count":55,"is_preprint":false},{"pmid":"33664294","id":"PMC_33664294","title":"A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33664294","citation_count":50,"is_preprint":false},{"pmid":"32899439","id":"PMC_32899439","title":"Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19.","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/32899439","citation_count":47,"is_preprint":false},{"pmid":"33585502","id":"PMC_33585502","title":"Structural Comparison of the SARS CoV 2 Spike Protein Relative to Other Human-Infecting Coronaviruses.","date":"2021","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33585502","citation_count":44,"is_preprint":false},{"pmid":"35652342","id":"PMC_35652342","title":"Association of Cardiovascular Health Through Young Adulthood With Genome-Wide DNA Methylation Patterns in Midlife: The CARDIA Study.","date":"2022","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/35652342","citation_count":42,"is_preprint":false},{"pmid":"32511472","id":"PMC_32511472","title":"Standardization of enzyme-linked immunosorbent assays for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling.","date":"2020","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32511472","citation_count":36,"is_preprint":false},{"pmid":"32963239","id":"PMC_32963239","title":"Consensus transcriptional regulatory networks of coronavirus-infected human cells.","date":"2020","source":"Scientific data","url":"https://pubmed.ncbi.nlm.nih.gov/32963239","citation_count":30,"is_preprint":false},{"pmid":"37794071","id":"PMC_37794071","title":"Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37794071","citation_count":23,"is_preprint":false},{"pmid":"33815307","id":"PMC_33815307","title":"Genomic Feature Analysis of Betacoronavirus Provides Insights Into SARS and COVID-19 Pandemics.","date":"2021","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/33815307","citation_count":21,"is_preprint":false},{"pmid":"33800363","id":"PMC_33800363","title":"Towards Quantitative and Standardized Serological and Neutralization Assays for COVID-19.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33800363","citation_count":17,"is_preprint":false},{"pmid":"35790048","id":"PMC_35790048","title":"WARS1 and SARS1: Two tRNA synthetases implicated in autosomal recessive microcephaly.","date":"2022","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/35790048","citation_count":14,"is_preprint":false},{"pmid":"36479439","id":"PMC_36479439","title":"RNA G-quadruplex forming regions from SARS-2, SARS-1 and MERS coronoviruses.","date":"2022","source":"Frontiers in chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36479439","citation_count":13,"is_preprint":false},{"pmid":"35617962","id":"PMC_35617962","title":"IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35617962","citation_count":12,"is_preprint":false},{"pmid":"40049166","id":"PMC_40049166","title":"VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation.","date":"2025","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/40049166","citation_count":11,"is_preprint":false},{"pmid":"36041817","id":"PMC_36041817","title":"Loss of seryl-tRNA synthetase (SARS1) causes complex spastic paraplegia and cellular senescence.","date":"2022","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36041817","citation_count":10,"is_preprint":false},{"pmid":"34570399","id":"PMC_34570399","title":"A bi-allelic loss-of-function SARS1 variant in children with neurodevelopmental delay, deafness, cardiomyopathy, and decompensation during fever.","date":"2021","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/34570399","citation_count":9,"is_preprint":false},{"pmid":"34929193","id":"PMC_34929193","title":"Negatively charged residues in the membrane ordering activity of SARS-CoV-1 and -2 fusion peptides.","date":"2021","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34929193","citation_count":9,"is_preprint":false},{"pmid":"34924802","id":"PMC_34924802","title":"Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions.","date":"2021","source":"Saudi journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34924802","citation_count":6,"is_preprint":false},{"pmid":"38069712","id":"PMC_38069712","title":"Comparison of the Old and New - Novel Mechanisms of Action for Anti-coronavirus Nucleoside Analogues.","date":"2022","source":"Chimia","url":"https://pubmed.ncbi.nlm.nih.gov/38069712","citation_count":6,"is_preprint":false},{"pmid":"38255739","id":"PMC_38255739","title":"Protein-Protein Interactions of Seryl-tRNA Synthetases with Emphasis on Human Counterparts and Their Connection to Health and Disease.","date":"2024","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38255739","citation_count":5,"is_preprint":false},{"pmid":"36380759","id":"PMC_36380759","title":"Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive protection across divergent subgroups.","date":"2022","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/36380759","citation_count":2,"is_preprint":false},{"pmid":"40737240","id":"PMC_40737240","title":"Binding of SARS-CoV-1/2 NSP1 to DNA Polymerase α-Primase Inhibits DNA Replication through Reduction of Interaction between DNA and DNA Polymerase α-Primase.","date":"2025","source":"Journal of chemical information and modeling","url":"https://pubmed.ncbi.nlm.nih.gov/40737240","citation_count":1,"is_preprint":false},{"pmid":"33849809","id":"PMC_33849809","title":"A novel SARS-CoV-2 IgG line-blot for evaluating discrepant IgG test results - Observations in pre-pandemic and follow-up samples of five patients.","date":"2021","source":"Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/33849809","citation_count":1,"is_preprint":false},{"pmid":"32511379","id":"PMC_32511379","title":"Consensus transcriptional regulatory networks of coronavirus-infected human cells.","date":"2020","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/32511379","citation_count":0,"is_preprint":false},{"pmid":"32365214","id":"PMC_32365214","title":"[Bats and humans].","date":"2020","source":"Lakartidningen","url":"https://pubmed.ncbi.nlm.nih.gov/32365214","citation_count":0,"is_preprint":false},{"pmid":"34909776","id":"PMC_34909776","title":"Critical Negatively Charged Residues Are Important for the Activity of SARS-CoV-1 and SARS-CoV-2 Fusion Peptides.","date":"2021","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/34909776","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15892,"output_tokens":1808,"usd":0.037398,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8304,"output_tokens":2555,"usd":0.052698,"stage2_stop_reason":"end_turn"},"total_usd":0.090096,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"Looking at the corpus, I need to identify which papers are about the human gene SARS1 (seryl-tRNA synthetase 1) versus papers using \"SARS1\" as an abbreviation for SARS-CoV-1 (the virus). The human gene SARS1 encodes seryl-tRNA synthetase 1.\n\nPapers clearly about human SARS1 gene:\n- [12] WARS1 and SARS1: Two tRNA synthetases implicated in autosomal recessive microcephaly\n- [16] Loss of seryl-tRNA synthetase (SARS1) causes complex spastic paraplegia and cellular senescence\n- [17] A bi-allelic loss-of-function SARS1 variant in children with neurodevelopmental delay...\n- [21] Protein-Protein Interactions of Seryl-tRNA Synthetases...\n- [15] VIPER-TACs leverage viral E3 ligases... (mentions SARS1 as pan-essential target protein)\n\nAll other papers use \"SARS1\" as abbreviation for SARS-CoV-1 virus — these are symbol collisions/different entities.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2022,\n      \"finding\": \"A missense variant in SARS1 (p.Arg213Leu) located directly within the enzyme's active site likely diminishes seryl-tRNA synthetase aminoacylation activity, as demonstrated by structural mapping placing the variant at the active site; patients with biallelic SARS1 variants present with microcephaly, developmental delay, intellectual disability, and brain anomalies.\",\n      \"method\": \"Structural mapping of variant onto SARS1 protein structure; clinical genetics with biallelic variant identification\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — structural mapping only (no in vitro enzymatic assay reported in abstract), single lab, no direct biochemical validation of activity reduction described\",\n      \"pmids\": [\"35790048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A de novo splice site deletion in SARS1 causing a 5-amino acid in-frame insertion near the active site results in loss-of-function with a dominant negative effect, as shown by complementation assays in S. cerevisiae and serylation assays in yeast and patient fibroblasts. Loss of SARS1 function causes cellular senescence, including abnormal cell shape, arrested division, increased beta-galactosidase staining, and elevated senescence-associated secretory phenotype markers (IL-6, p21, p16, p53).\",\n      \"method\": \"Yeast complementation assay; serylation (aminoacylation) activity assay in yeast and patient fibroblasts; beta-galactosidase staining; immunofluorescence/cell morphology; SASP marker measurement\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct enzymatic (serylation) assay confirming loss of function, complementation assay in yeast model, multiple orthogonal methods (enzymatic activity + cell biology phenotypes), single lab\",\n      \"pmids\": [\"36041817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A biallelic missense variant in SARS1 (p.Arg213Leu) leads to protein instability, reduced protein level, and reduced enzymatic (seryl-tRNA synthetase) activity, causing a neurodevelopmental syndrome including developmental delay, central deafness, cardiomyopathy, and metabolic decompensation.\",\n      \"method\": \"Protein stability assessment; enzymatic activity assay for aminoacylation in patient-derived cells; clinical genetics\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct enzymatic activity measurement and protein level quantification, single lab, two orthogonal methods\",\n      \"pmids\": [\"34570399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Human cytosolic SARS1 (SerRS) interacts with m3C32 tRNA methyltransferases, coordinates tRNA modification and aminoacylation; when translocated to the nucleus, SerRS acts as a negative regulator of VEGFA gene expression by competing with transcription factors NFκB1 and c-Myc, forming complexes with YY1 and SIRT2. SerRS phosphorylation in hypoxia diminishes its binding to the VEGFA promoter, and nutrient deprivation triggers SerRS glycosylation that reduces its nuclear localization. SerRS also binds telomeric DNA and cooperates with shelterin protein POT1 to regulate telomere length and cellular senescence.\",\n      \"method\": \"Review/synthesis of prior experimental findings including co-immunoprecipitation, nuclear localization experiments, chromatin immunoprecipitation, post-translational modification studies (phosphorylation/glycosylation), and protein interaction assays (cited from primary literature reviewed)\",\n      \"journal\": \"Life (Basel, Switzerland)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — review paper summarizing multiple experimental results from prior primary studies; individual findings supported by multiple orthogonal methods across studies, but this corpus only contains the review abstract\",\n      \"pmids\": [\"38255739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SARS1 (seryl-tRNA synthetase 1) is identified as a pan-essential target protein in the context of HPV-positive cancer cells; the HPV E6 viral E3 ubiquitin ligase can be used to degrade SARS1 via VIPER-TAC bifunctional molecules, selectively killing E6-expressing cancer cells.\",\n      \"method\": \"Targeted protein degradation (VIPER-TAC) in HPV-positive cervical cancer cell model; cell viability assay\",\n      \"journal\": \"Cell chemical biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single-lab proof-of-concept, demonstrates degradability of SARS1 via exogenous E3 ligase but does not characterize SARS1's own enzymatic mechanism; no direct mechanistic study of SARS1 function\",\n      \"pmids\": [\"40049166\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SARS1 (seryl-tRNA synthetase 1) is a cytosolic aminoacyl-tRNA synthetase that catalyzes the ligation of serine to its cognate tRNA (serylation), an essential step in protein synthesis; loss-of-function variants cause neurodevelopmental disorders with a dominant negative or recessive mechanism, and SARS1 has non-canonical roles including nuclear translocation to repress VEGFA transcription (in complex with YY1 and SIRT2), interaction with m3C32 tRNA methyltransferases, binding of telomeric DNA in cooperation with POT1 to regulate telomere length, and regulation of cellular senescence.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SARS1 (seryl-tRNA synthetase 1) is a cytosolic aminoacyl-tRNA synthetase that ligates serine to its cognate tRNA, an essential step in protein synthesis whose loss is incompatible with normal cellular maintenance [#1]. Direct serylation assays in patient fibroblasts and yeast complementation establish that disease-associated SARS1 variants impair aminoacylation activity, and loss of function drives cellular senescence marked by arrested division, beta-galactosidase accumulation, and elevated SASP factors (IL-6, p21, p16, p53) [#1]. A recurrent biallelic active-site missense variant (p.Arg213Leu) destabilizes the protein and reduces enzymatic activity, causing a neurodevelopmental syndrome with developmental delay, deafness, cardiomyopathy, and metabolic decompensation [#2]; SARS1 variants are thus causative of recessive and dominant-negative neurodevelopmental disorders [#1, #2]. Beyond catalysis, SARS1 coordinates tRNA modification through interaction with m3C32 tRNA methyltransferases and exerts non-canonical nuclear functions, including repression of VEGFA transcription in complexes with YY1 and SIRT2 and binding of telomeric DNA in cooperation with POT1 to regulate telomere length, with these activities tuned by hypoxia-driven phosphorylation and nutrient-dependent glycosylation [#3]. SARS1 is a pan-essential dependency that can be selectively degraded in HPV-positive cancer cells [#4].\",\n  \"teleology\": [\n    {\n      \"year\": 2021,\n      \"claim\": \"Establishing whether a recurrent SARS1 active-site variant is biochemically deleterious connected the gene to a defined neurodevelopmental syndrome and showed the mechanism is protein destabilization plus catalytic loss, not merely sequence change.\",\n      \"evidence\": \"Protein stability assessment and aminoacylation activity assay in patient-derived cells with clinical genetics\",\n      \"pmids\": [\"34570399\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\n        \"Did not test rescue/complementation to formally prove causality\",\n        \"Mechanism by which the variant destabilizes the protein not structurally resolved\",\n        \"Tissue-specific basis of the syndrome (deafness, cardiomyopathy) not addressed\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mapping a biallelic missense variant to the active site and linking biallelic SARS1 to microcephaly and brain anomalies extended the disease phenotype but rested only on structural inference of activity loss.\",\n      \"evidence\": \"Structural mapping of the variant onto SARS1 structure with biallelic-variant clinical genetics\",\n      \"pmids\": [\"35790048\"],\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\n        \"No in vitro enzymatic assay reported to confirm the predicted activity reduction\",\n        \"Single lab, no functional rescue\",\n        \"Genotype-phenotype correlation across SARS1 patients not unified\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Direct serylation and yeast complementation assays proved that a SARS1 splice variant causes loss of function with a dominant-negative effect and, critically, that this loss drives cellular senescence — connecting tRNA charging deficiency to a defined cellular phenotype.\",\n      \"evidence\": \"Yeast complementation, serylation assays in yeast and patient fibroblasts, beta-galactosidase staining, morphology, and SASP marker measurement\",\n      \"pmids\": [\"36041817\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\n        \"Molecular route from aminoacylation loss to senescence induction not delineated\",\n        \"Whether dominant-negative action reflects subunit poisoning not directly shown\",\n        \"In vivo organismal phenotype not modeled\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Synthesis of prior primary data positioned SARS1 as a moonlighting protein beyond translation — coordinating tRNA modification, repressing VEGFA transcription in the nucleus, and binding telomeric DNA — defining a regulatory dimension to its biology.\",\n      \"evidence\": \"Review consolidating co-IP, nuclear localization, ChIP, post-translational modification, and interaction assays from prior studies\",\n      \"pmids\": [\"38255739\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\n        \"Corpus contains only the review abstract, not the underlying primary datasets\",\n        \"Signals controlling nuclear translocation versus cytosolic catalysis not fully mapped\",\n        \"Functional contribution of telomeric/VEGFA roles to the disease phenotype unestablished\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrating that SARS1 is a pan-essential protein degradable via the HPV E6 E3 ligase showed it can be exploited as a selective vulnerability in virus-positive cancer cells.\",\n      \"evidence\": \"VIPER-TAC targeted degradation in HPV-positive cervical cancer cells with viability readout\",\n      \"pmids\": [\"40049166\"],\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\n        \"Proof-of-concept degradation only; does not characterize SARS1's own catalytic mechanism\",\n        \"Selectivity and off-target effects in non-cancer cells not detailed\",\n        \"Single-lab study\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SARS1's non-canonical nuclear and telomeric functions are mechanistically coupled to — or separable from — its essential aminoacylation activity, and how each contributes to senescence and neurodevelopmental disease, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\n        \"No structural model linking active-site variants to dominant-negative subunit behavior\",\n        \"Direct primary evidence for VEGFA/telomere roles absent from this corpus\",\n        \"Causal chain from charging defect to senescence and tissue pathology undefined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"YY1\", \"SIRT2\", \"POT1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":4,"faith_total":5,"faith_pct":80.0}}